Apollo Hospitals to deepen presence in Bengaluru, Hyderabad
Apollo Hospitals Enterprise Ltd is increasing its penetration in Bengaluru and Hyderabad through a mix of greenfield and brownfield projects, as it embarks on a large-scale expansion plan in FY26.
The hospital chain has approved a brownfield expansion of 160 beds across Jubilee Hills and Secunderabad facilities in Hyderabad, as well as acquired 2.53-acre land in Sarjapur, Bengaluru for a 500-bed greenfield hospital. These are expected to be operational in 3-4 years.
It has also acquired an existing 200-bed hospital in Sarjapur, which will be operational in the next two quarters, the company said. This is in addition to the chain's planned expansion in Gurugram, Hyderabad, Kolkata and Pune, which it is commencing in FY26.
Also read: IHH Healthcare arm increases damages sought from Daiichi Sankyo to ₹11,800 crore over Fortis stake dispute
'Over the next one year, we will be having quite a bit of expansions coming up," chief financial officer Krishnan Akhileswaran told Mint.
The chain will be adding over 4,300 beds over three to four years beginning FY26, with a total capital outlay of over ₹8,000 crore.
In the fourth quarter ended March, the company's consolidated revenues rose 13% year-on-year to ₹5,592 crore. Consolidated ebitda increased 20% over a year earlier to ₹770 crore, while profit after tax (PAT) rose 54% to ₹390 crore.
For FY25, Apollo's consolidated revenues rose 14% on-year to ₹21,794 crore, while ebitda grew 26% to ₹3,022 crore. PAT increased 61% to ₹1,446 crore.
Also read: Zydus bets big on vaccines and medtech
Hospitals business grows
The company's hospitals business grew 10% year-on-year in Q4 to ₹2,822 crore, while ebitda grew 16% to ₹686.3 crore. The business reported an ebitda margin of 24.3%.
'All of this is clearly representative of the operating leverage that we have from the same facilities that we are operating out of. No new facilities added as yet," Krishnan said. The growth from the company's bed additions starting this year will be significantly seen in FY27, he said.
The company saw a dip in volumes due to the loss of patients from Bangladesh. However, the current base is the lowest it can get to, Krishan said.
Also read: Access to obesity management not available to most Indian patients: World Heart Federation report
The company expects Apollo 24/7 to be profitable by the end of FY26. It is focusing on 20% growth for Apollo Healthco, its digital healthcare and omnichannel pharmacy arm in FY26.
'The focus [for Apollo Healthco] is more on revenue and profitability," Krishnan said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
15 minutes ago
- Fashion Value Chain
Swiss Military Opens First Exclusive Outlet in India
Global lifestyle brand Swiss Military has launched its first-ever Exclusive Brand Outlet (EBO) in Surat, Gujarat, marking a significant step in the brand's expansion across India. Known for delivering premium travel gear and lifestyle essentials in over 26 countries, Swiss Military's latest move underlines its growing focus on the Indian market. The Surat EBO showcases the full spectrum of the brand's products, including polycarbonate and polypropylene luggage, premium backpacks, business bags, and India's first kids' trolley range. The store boasts international-standard design, sleek aesthetics, and immersive merchandising, bringing a global retail experience to Indian consumers. 'With this launch, India becomes central to our growth vision,' said Anuj Sawhney, Managing Director. 'Surat is one of our highest-performing markets, making it the ideal launchpad for our exclusive store format.' Already present in over 4,000 retail touchpoints across India, Swiss Military's EBO format aims to deepen its connection with aspirational consumers who seek quality, innovation, and style. The store's opening day saw over 1,000 visitors, with exclusive promotions and immersive brand experiences. To explore the full collection, visit:
Mint
21 minutes ago
- Mint
Trump tariffs: Here's how Indian exporters of apparel, drugs and tyres are preparing for all contingencies
New Delhi/Mumbai: Indian exporters of apparel, automotive parts, pharmaceuticals and tyres – with significant shipments to the US – are preparing contingency plans or revising their business strategies to mitigate the business risk from the imposition of tariffs. US President Donald Trump's administration has imposed a 10% universal tariff on all imports from every country, including India. Gokaldas Exports Ltd, a listed garments exporter, will focus on expanding its business in Europe because tariffs have hurt business with its main export market – the US. 'Since there is a lot of tariff uncertainty, we are pivoting to Europe. The idea is not to reduce our US business in absolute terms, but for incremental business we will focus on Europe including the UK," said Sivaramakrishnan Ganapathi, managing director of Gokaldas Exports. Margins of apparel exporters including Gokaldas have come under pressure following the tariff levy. US retailers have been unable to pass on the increased cost to consumers and are pushing for their suppliers to share the burden, Ganapathi said. Also Read | As US court declares Trump's tariffs illegal, experts urge India to reassess trade talks 'In the short term, we may also have to bear some of that cost just to keep up the relationships," he said. Gokaldas got about three-fourths of its ₹3,864 crore FY25 revenue from the US. The US is the largest export destination for Indian apparel exports. This is because competing apparel-exporting nations Bangladesh, Vietnam, Sri Lanka and Pakistan get preferential tariff rates in Europe, putting Indian exporters at a disadvantage. India's in-principle trade agreement with the UK last month and progressing talks with the European Union could now level the playing field for Indian exporters. 'Once an FTA with the UK is finalised, it will bring at least a $1 billion apparel export opportunity for India. The opportunity in the EU will be much larger. We should ready ourselves up for this incremental business," Ganapathi said. India exported readymade garments worth $16 billion ( ₹1.35 trillion) in FY25, as per data from the Apparel Export Promotion Council, an industry group. India business Indian tyre companies are chalking out similar contingency plans. The US is a key export market for Indian tyremakers, constituting about one-fifth of the country's total overseas tyre sales of $3 billion in FY24. Balkrishna Industries Ltd, which gets almost three-fourths of its revenue from exports, will focus on expanding business in India with a series of product launches. The company now targets 8% of the global tyre market by 2030 compared with its earlier goal of a 10% share. "Please note that we are under a slow-moving economy. There are wars happening, there are trade wars happening. Uncertain times are there. So that is why we are looking at it very conservatively," Rajiv Poddar, managing director at Balkrishna Industries, said on an earnings call on 24 May. 'In case anything changes and there's a catalyst, we are absolutely ready to pounce on that opportunity and go back to our original vision of 10%." Also Read | India's exports face geopolitical woes but trade deals offer relief: RBI report Ceat, which acquired Canada's Camso in December, is betting that India will be successful in signing a bilateral trade pact with the US before Sri Lanka and is planning to change its tyre distribution accordingly. Camso gets 30% of its business from the US through its two manufacturing facilities in Sri Lanka. "In case the tariffs go through, we will produce for the United States from Indian facilities if tariffs are lower here and for Europe from Sri Lanka," said Arnab Banerjee, managing director and CEO at Ceat. Apprehensive pharma Indian pharmaceutical companies are exploring partnerships and investment opportunities to manufacture in the US. While the pharmaceuticals sector has not been slapped with tariffs yet by the US, Indian exporters are apprehensive of surprise levies by Trump. 'We have a very good balance sheet; we have a very healthy financial capacity. We are always looking for opportunities," Dr. Reddy's Laboratories chief executive Erez Israeli said last month on investing in the US. 'We are not rushing, and we are not obliged for any commitment… But we certainly want to be in the United States long term. We will look for the relevant opportunity for us." Also Read | Bitter pill for Indian pharma as Trump tariffs could hurt exports by $2.25 billion The contingency plans of pigment manufacturer Sudarshan Chemicals include leveraging its ₹1,180 crore acquisition of Germany's Heubach Group. Heubach has a plant in the US as well as 19 units in Europe, allowing it the flexibility to tweak its distribution depending on the tariff scenario. "The new acquisition gives us a lot of flexibility. If there are tariffs on India, we supply from Europe into the US market," Rajesh Rathi, managing director of Sudarshan Chemicals, told Mint in March. Jessica Jani in Mumbai contributed to this story.
Mint
24 minutes ago
- Mint
AVIC Chengdu to Beijing Navigation Control - Chinese defence stocks volatile amid fading India-Pakistan tensions
Chinese defence stocks witnessed heightened activity on Tuesday, tracking gains in the broader China stock market. Shares of AVIC Chengdu Aircraft, the manufacturer of the J-10 fighter jets, were particularly in focus amid the recent military conflict between India and Pakistan. The Hang Seng China A Aerospace & Defence Index surged 13% over just six trading sessions — from April 13 to May 12 — coinciding with the onset of the India-Pakistan conflict in early May. The rally was driven by expectations of increased Chinese arms exports to Pakistan as tensions escalated. However, the rally lost steam following the announcement of a ceasefire agreement between the two nations, which helped ease fears of a prolonged conflict. Subsequently, the index declined nearly 8% over the next 12 sessions until May 28. In a sign of renewed buying interest, the index of the Chinese defence stocks has since gained over 4% in the last three trading sessions. Hang Seng China A Aerospace & Defence Index is still down 5% from May 12 high. Several constituent stocks of the index, including Tellhow Sci-Tech, Beijing Navigation Control, Jiangsu Maixinlin Aviation Science and Technology, Tianqin Equipment, and Beijing Hengyu Datacom Aviation Equipment Co, have declined between 5% and 10% over the past month. AVIC Chengdu Aircraft, the manufacturer of the J-10 fighter jets used by Pakistan, remained in the spotlight during the peak of the India-Pakistan conflict. However, the bullish momentum in the stock has since faded. AVIC Chengdu share price has plummeted over 20% from their May peak, falling from a high of 95.86 yuan on May 12 to a low of 76.70 yuan in just 15 sessions. The decline in AVIC Chengdu Aircraft share price was exacerbated after Indian Prime Minister Narendra Modi publicly questioned Pakistan's claims that Chinese-made fighter jets were responsible for the destruction of the Indian Air Force's Adampur airbase. Investor sentiment on Chinese Defence stocks also turned cautious following the successful completion of India's Operation Sindoor, which showcased India's military capabilities. Additionally, the ceasefire agreement between India and Pakistan has reduced the urgency and potential for immediate defence procurement, further dampening interest in Chinese defence counters. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
